Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00448409 · ClinicalTrials.gov registry record · Phase 2
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00448409 is a Phase 2 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 27 participants.
The verdict
NCT00448409, a Phase 2 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of Trovax and GM-CSF in patients with prostate cancer.
Interventions
- DRUG GM-CSF
- BIOLOGICAL TroVax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00448409
The ClinicalTrials.gov registry entry for NCT00448409 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GM-CSF is the first listed.
NCT00448409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00448409 about?
NCT00448409 is a clinical study titled "Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer". To evaluate the efficacy and safety of Trovax and GM-CSF in patients with prostate cancer.
What is the current status of trial NCT00448409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2006-05. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00448409?
The interventions under investigation include: GM-CSF (DRUG), TroVax (BIOLOGICAL).
Who is sponsoring clinical trial NCT00448409?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.